2025
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumab
2024
Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment
Orive D, Echepare M, Bernasconi-Bisio F, Sanmamed M, Pineda-Lucena A, de la Calle-Arroyo C, Detterbeck F, Hung R, Johansson M, Robbins H, Seijo L, Montuenga L, Valencia K. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment. Archivos De Bronconeumología 2024, 60: s67-s76. PMID: 39079848, PMCID: PMC12172408, DOI: 10.1016/j.arbres.2024.07.007.Peer-Reviewed Original ResearchLung cancer screeningLung cancerCancer screeningManagement of lung cancerLDCT-based lung cancer screeningSurgically resected tumorsPresence of metastasesEarly lung cancerCancer-related deathsLung cancer patientsContext of lung cancer screeningDiagnosis to earlier stagesProtein biomarkersResected tumorProtein-based biomarkersTherapeutic optionsAdjuvant strategiesLate diagnosisCancer patientsRecommended management strategiesEarly managementLung cancer detectionRobust biomarkersBenefit patientsCancerPerioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2016
Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract
Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, Bassi C, Salvia R, Malleo G, Paiella S, Wolfgang C, Matthaei H, Offerhaus G, Adham M, Bruno M, Reid M, Krasinskas A, Klöppel G, Ohike N, Tajiri T, Jang K, Roa J, Allen P, Castillo C, Jang J, Klimstra D, Hruban R. Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract. Annals Of Surgery 2016, 263: 162-177. PMID: 25775066, PMCID: PMC4568174, DOI: 10.1097/sla.0000000000001173.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmTumoral intraepithelial neoplasmsIntraepithelial neoplasmMucinous neoplasmsHigher grades of dysplasiaGrade of dysplasiaEffective management algorithmsNon-invasive componentInternational multidisciplinary groupResected tumorTumor characteristicsInvasive carcinomaInvasive componentInvasive sizePathological evaluationImaging findingsPancreas groupRare casePancreatobiliary tractFrozen sectionsAccurate comparison of dataLesion sizeNeoplasmsDuct diameter
2014
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Boj S, Hwang C, Baker L, Chio I, Engle D, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector M, Gracanin A, Oni T, Yu K, van Boxtel R, Huch M, Rivera K, Wilson J, Feigin M, Öhlund D, Handly-Santana A, Ardito-Abraham C, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov G, Delcuze B, Creighton B, Wright K, Park Y, Morsink F, Molenaar I, Rinkes I, Cuppen E, Hao Y, Jin Y, Nijman I, Iacobuzio-Donahue C, Leach S, Pappin D, Hammell M, Klimstra D, Basturk O, Hruban R, Offerhaus G, Vries R, Clevers H, Tuveson D. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell 2014, 160: 324-338. PMID: 25557080, PMCID: PMC4334572, DOI: 10.1016/j.cell.2014.12.021.Peer-Reviewed Original ResearchConceptsPancreatic cancerSpectrum of tumor developmentPancreatic organoidsOrganoid modelsDuctal pancreatic cancerHuman pancreas tissueResected tumorMetastatic carcinomaLate diagnosisPancreatic tumorigenesisDeadly malignancyTumor developmentLethal malignancyDisease progressionSurvive cryopreservationPancreas tissueOrganoidsMalignancyGenetic cooperationCancerHuman tissuesProtein changesProteomic analysisTissueInterrogate pathways
2005
Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma
Jarnagin W, Bowne W, Klimstra D, Ben-Porat L, Roggin K, Cymes K, Fong Y, DeMatteo R, D'Angelica M, Koea J, Blumgart L. Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma. Annals Of Surgery 2005, 241: 703-714. PMID: 15849506, PMCID: PMC1357125, DOI: 10.1097/01.sla.0000160817.94472.fd.Peer-Reviewed Original ResearchConceptsResection of hilar cholangiocarcinomaPapillary tumorsHilar cholangiocarcinomaR0 resectionResected tumorNodular sclerosingProportion of R0 resectionPredictors of favorable outcomeBloc partial hepatectomyDisease-specific survivalNodular sclerosing subtypePredictors of survivalGross resectionOperative deathsOperative mortalityPapillary carcinomaInvasive carcinomaInvasive tumorsPapillary componentConsecutive resectionsInvasive componentClinical behaviorImproved survivalHistopathological featuresFavorable outcome
1998
Factors Predictive of Survival in Ampullary Carcinoma
Howe J, Klimstra D, Moccia R, Conlon K, Brennan M. Factors Predictive of Survival in Ampullary Carcinoma. Annals Of Surgery 1998, 228: 87-94. PMID: 9671071, PMCID: PMC1191432, DOI: 10.1097/00000658-199807000-00013.Peer-Reviewed Original ResearchConceptsKaplan-Meier methodRate of resectionAmpullary carcinomaAmpulla of VaterNegative nodesOverall survivalPeriampullary adenocarcinomaImproved survivalFactors predictive of improved survivalFactors PredictiveMemorial Sloan-Kettering Cancer Center experiencePredictive of improved survivalMemorial Sloan-Kettering Cancer CenterFactors predictive of survivalSurvival of patientsLog-rank testCox proportional hazards regressionPredictive of survivalProportional hazards regressionResected tumorNegative marginsPathology reviewPeriampullary tumorsPrognostic factorsAmpullary tumors
1997
K-ras mutation in adenomas and carcinomas of the ampulla of vater.
Howe J, Klimstra D, Cordon-Cardo C, Paty P, Park P, Brennan M. K-ras mutation in adenomas and carcinomas of the ampulla of vater. Clinical Cancer Research 1997, 3: 129-33. PMID: 9815548.Peer-Reviewed Original ResearchConceptsK-ras mutationsAmpulla of VaterK-ras exon 1Patient survivalK-rasClinicopathological factorsExon 1Tumor size >2 cmAssociated with K-ras mutationK-ras mutation statusAnalysis of K-ras mutationsLog-rank testCox proportional hazards modelsAdjacent to carcinomaSpectrum of mutationsProgression of tumorsProportional hazards modelResected tumorAmpullary tumorsInvasive carcinomaMutation statusAmpullary carcinomaPCR amplificationColorectal neoplasmsPCR products
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply